The VIC Investor Network (VIN) invests in companies with exceptional intellectual property foundations in healthcare and emerging technology areas
VIN addresses the primary challenges of angel investing in science and technology-driven innovation
Co-investment on same terms with larger investors and built-in investment safeguards
Investments may be made as low as $5k per invested company allowing more investments and portfolio diversification
Secondary market for VIN shares gives members opportunity for liquidity prior to portfolio exits
Turnkey support through all stages of portfolio companies’ development.
Incubate high-potential ideas for future VIC portfolio companies.
Equity funding for proof-of-concept through commercial product roll-out.
Series A/B funding to reach major value-enhancing milestones
Companies built from the ground up based on high impact technologies exclusively licensed from top research institutions around the world. View All Companies
SFC Fluidics is a medical device company whose drug delivery platform can dramatically improve therapy compliance in diabetes.
Zebra Analytix is focused on creating game-changing analytical solutions spanning diverse, high-impact applications where rapid detection is essential
Akeso Biomedical is an animal performance and food safety company developing new solutions to improve gut health and treat bacterial infections using a broad-spectrum chemistry.
ACQUIRED | Ascendant Dx is a bioscience company whose mission is to commercialize disruptive diagnostic technologies aiding identification and treatment for diseases of women and children.
BiologicsMD is developing highly targeted, novel human therapeutics for hair loss diseases and conditions, as well as severe bone disorders.
BlueInGreen (BIG) designs, manufactures and services the most efficient gas dissolution equipment for water and wastewater treatment.
